Indeed, β-cell-targeted disruption of glucose metabolism through β-cell selective deletion of glucokinase induces a very severe diabetic phenotype with early neonatal lethality54, in contrast to milder, glucose intolerance observed with tamoxifen-induced β-cell-targeted Swell1 deletion. The gene discussed is LRRC8A; the disease is Glucose intolerance.